Evaluation of soluble HLA-G as a biomarker for multiple sclerosis

Neurology

Volumn 77, Issue 6, 2011, Pages 596-598

  Waschbisch, A ^a   Sandbrink, R ^b,c   Hartung, H P ^c   Kappos, L ^d   Schwab, S ^a   Pohl, C ^b,e   Wiendl, H ^f  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; HLA G ANTIGEN; INTERFERON BETA SERINE; PLACEBO; BETA INTERFERON; BIOLOGICAL MARKER; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-G ANTIGEN;

AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICALLY ISOLATED SYNDROME; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; ARTICLE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; LONGITUDINAL STUDY; PHASE 3 CLINICAL TRIAL; REGRESSION ANALYSIS;

BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; REGRESSION ANALYSIS;

EID: 80053305225     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318228c14d     Document Type: Note

References (7)

1. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008;29:125-132.
2. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
3. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens 2006;67:111-116.
4. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001;57:15-21.
5. Wiendl H, Feger U, Mittelbronn M, et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005;128:2689-2704.
6. Fainardi E, Rizzo R, Melchiorri L, et al. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis. Mult Scler 2008;14:446-454.
7. Fainardi E, Rizzo R, Melchiorri L, et al. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler 2006;12:2-12.